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ABSTRACT
The role of allogeneic transplantation in patients with de novo acute myeloid leukemia in first complete
remission (AML-CR1) is controversial. Aiming to preserve a graft-versus-leukemia effect, but minimize
morbidity and mortality from conditioning-related toxicity and graft-versus-host disease (GVHD), we con-
ducted a prospective multicenter study of reduced-intensity conditioning (RIC) as preparation for peripheral
blood stem cell sibling allografts in patients with intermediate or poor risk AML-CR1. Conditioning consisted
of fludarabine 125 mg/m2 and cyclophosphamide 120 mg/kg. Thirty-four patients were transplanted with a
median age of 45 years; 85% had intermediate risk cytogenetics. Early toxicity was minimal. The overall
incidence of grade II-IV acute GVHD was low (21%), but the 3 patients (9%) who developed grade IV GVHD
died. Donor T cell chimerism was rapid and generally complete, but complete myeloid chimerism was delayed.
Thirteen patients (38%) relapsed, 12 within a year of transplant. The estimated disease-free survival (DFS) and
overall survival at 2 years was 56% (95% confidence interval [CI] 39%-71%) and 68% (95% CI 50%-81%),
respectively. The incidence of extensive chronic GVHD (cGVHD) was low (24% of surviving patients at 12
months) and most survivors had an excellent performance status. These observations justify a prospective
comparison of RIC versus myeloablative conditioning allografts for AML-CR1.
© 2007 American Society for Blood and Marrow Transplantation
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rNTRODUCTION
The optimal treatment approach for patients in
rst complete remission (CR1) of acute myeloid leu-
emia (AML) remains controversial. For younger pa-
ients, options have included an autograft consoli-
ation with high-dose cytosine arabinoside or an
llograft from a human leukocyte antigen (HLA)-
atched compatible sibling donor using myeloabla- (
60ive conditioning. Interpretation of the results of ran-
omized studies addressing which of these approaches
s superior is complex, as study designs vary and only
minority of patients in remission actually receive the
llocated treatment [1]. In general, however, a my-
loablative allograft has produced the lowest risk of
elapse but minimal improvement in overall survival
OS) resulting from treatment-related mortality (TRM)
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Peripheral Blood Stem Cell Sibling Allografts 561rom the conditioning regimen and graft versus host
isease (GVHD) [2].
The therapeutic options for AML-CR1, particu-
arly for older patients, expanded in the late 1990s
fter the demonstration that reduced-intensity condi-
ioning (RIC) regimens using peripheral blood stem
ells (PBSC) produced durable donor engraftment
nd permitted immune-mediated graft-versus-tumor
ffects, with a reduction in TRM because of reduced
ajor organ damage during conditioning and lower
ates of severe acute GVHD (aGVHD) [3,4]. The
ower TRM is particularly relevant when dealing with
malignancy such as AML-CR1 with intermediate
isk cytogenetics in which a reasonable cure rate can
e expected without transplantation [5]. However, the
ustiﬁcation for using RIC regimens, which are truly
onmyeloablative and have only a modest antileuke-
ic effect in AML-CR1, depends on demonstration of
n acceptably low relapse rate from a graft-versus-
eukemia (GVL) effect with acceptable morbidity from
hronic GVHD (cGVHD).
In 2001, the Australasian Leukaemia and Lym-
homa Group (ALLG) commenced a prospective
ulticenter study of RIC HLA-compatible sibling
BSC allografts for adult patients with AML-CR1.
hree issues were addressed in discussions on study
esign: (1) eligibility according to risk of relapse,
2) conditioning regimen, and (3) optimal GVHD
rophylaxis. The study was largely restricted to pa-
ients with intermediate risk cytogenetics [6], based in
art on observations from the United Kingdom Med-
cal Research Council (UK MRC) that myeloablative
llografting for AML-CR1 was only seen to provide a
eneﬁt in disease-free survival (DFS) and OS in this
roup of patients [7]. Patients with adverse cytogenet-
cs (5, 7, del[5q], or abnormalities of 3q) were
ncluded in this study at the investigator’s discretion.
We wished to examine the effect of a highly im-
unosuppressive conditioning regimen that was non-
yeloablative and caused minimal mucositis on the
isk of relapse and GVHD. We selected high-dose
yclophosphamide 120 mg/kg and standard dose ﬂu-
arabine 125 mg/m2 (ﬂu-cyclo) as the conditioning
egimen, as this regimen caused minimal mucositis
nd had been demonstrated to produce rapid donor T
ell chimerism without a high incidence of severe
VHD in solid tumor patients when used in conjunc-
ion with cyclosporine as GVHD prophylaxis [8].
oreover, high-dose cyclophosphamide was a com-
onent of effective myeloablative regimens such as
yclophosphamide- total body irradiation (TBI) and
usulphan-cyclophosphamide. It was considered that
udarabine low-dose cyclophosphamide (2 g/m2)3
ay not be sufﬁciently immunosuppressive to reliably
acilitate rapid donor engraftment in this group;
hereas another widely used RIC regimen at the time,
udarabine-melphalan (ﬂu-mel; 120-140 mg/m2), was 6ot chosen as it is effectively myeloablative, reliably
roducing early, complete donor T and myeloid cell
ngraftment and gastrointestinal toxicity leading to a
ate of aGVHD comparable to that of a conventional
yeloablative regimen [9].
We elected to use standard GVHD prophylaxis
ith cyclosporine and short course methotrexate.
n vivo or ex vivo T cell depletion was not used to
void abrogation of any potential T cell-mediated
VL effect.
The primary aims of the study were to evaluate the
inetics of T cell and myeloid chimerism, to relate
hese to the incidence and severity of GVHD, and to
ssess the overall tolerability of the RIC regimen with
espect to early mucositis, nonhematologic toxicity,
nd, performance status in long-term survivors. The
econdary aims included an assessment of DFS (mea-
ured from the date of transplant to the earlier of the
ate of relapse or the date of death from any cause)
nd OS.
ATIENTS AND METHODS
ligibility
Patients were enrolled if they met the following
ligibility criteria: (a) had a conﬁrmed diagnosis of de
ovo AML (other than FAB group M3) now in ﬁrst
R; (b) had at least 1 course of consolidation therapy
fter achieving CR (patients were not excluded if they
equired more than 1 induction cycle to achieve CR);
c) were aged between 18-65 years inclusive, and if
ged between 55 and 65 years, had an ECOG perfor-
ance status score 2; (d) had intermediate or ad-
erse risk group cytogenetics and a fully compatible
ibling donor; (e) had adequate organ function includ-
ng creatinine clearance 30 mL/min; and (f) had
iven written informed consent to participate in the
tudy prior to the commencement of conditioning.
The study was approved by the Human Research
thics Committees at each of the participating insti-
utions.
tudy Protocol
Conditioning therapy consisted of cyclophospha-
ide 60 mg/kg intraveneously (i.v.) on days 7 and
6 and ﬂudarabine 25 mg/m2 i.v. on days 5 to 1
nclusive. In patients with a body mass index (BMI)
27, doses were based on the body weight for the
atient’s height calculated to give a BMI of 27.
To mobilize PBSC, donors received ﬁlgrastim
Neupogen, AMGEN, Thousand Oaks, CA) 8 g/kg
wice daily by subcutaneous injection with the ﬁrst
eukapheresis performed on the fourth day of ﬁlgras-
im. The intent was to collect a minimum of 3  106
D34 cells/kg recipient weight and preferably at least
 106 CD34 cells/kg.
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A. P. Grigg et al.562Graft-versus-host-disease prophylaxis consisted of
ethotrexate 15 mg/m2 on day 1, 10 mg/m2 on days
, 6, and 11, and cyclosporine 3 mg/kg IV from day
1, switched to oral administration from days 10-20.
yclosporine was tapered according to day 30 T cell
himerism results. If 50% donor, cyclosporine was
apered from day 100 to day 180 in the absence of
igniﬁcant GVHD. If 50% donor, cyclosporine was
apered over the next 30. aGVHD requiring therapy
as treated with 2 mg/kg methylprednisolone i.v. in
ddition to full-dose cyclosporine. Antimicrobial pro-
hylaxis was at the discretion of each investigator
ccording to local institution policy.
Patients were eligible to receive donor leukocyte
nfusions (DLIs) if they had ceased cyclosporine at
east 2 weeks prior, had experienced less than grade 2
VHD and had (1) successive blood samples 4 weeks
part within the ﬁrst 6 months posttransplant demon-
trating progressive loss of donor T cell chimerism (or
ersistently 50% donor T cells), or (2) recurrent
isease.
aboratory Investigations
Chimerism studies on T cell and myeloid subsets
f peripheral blood samples were scheduled in remis-
ion patients at days 30, 90, 180, 270, and 365 and
erformed as previously published [9]. In patients with
50% donor T cell chimerism at day 30 undergoing
rapid cyclosporine taper, chimerism was repeated at
ay 60. Serial fertility assessments posttransplant were
erformed in a subset of nonvasectomized males and
remenopausal females.
tatistics
Estimates of cumulative incidences and their stan-
ard errors of achievement of “full” (95%) donor
himerism (T cell or myeloid), were calculated. The
ssociation between donor chimerism and the inci-
ence and severity of aGVHD was studied by com-
aring the maximum percentage of donor cells ob-
erved in the ﬁrst 100 days following allograft with the
orst grade of aGVHD recorded at the day 100 as-
essment. Maximum donor chimerism percentages for
atients in the 3 aGVHD severity groups (0, I-II, and
II-IV) were compared using the exact form of the
ruskal-Wallis Test and the exact form of the Wil-
oxon 2-sample test for patients in the 2 aGVHD
ncidence groups (0 and I-IV). Correlations were cal-
ulated to assess the association between maximum
onor chimerism percentages and transfused CD34
evels.
For incidences such as the rate of aGVHD, Blyth-
till-Casella 95% conﬁdence intervals were calcu-
ated. The Kaplan-Meier product limit method was
sed to estimate OS, DFS, and also remission dura-
ion (the latter being censored by deaths without prior Celapse). Accrual closed in December 2004, and the
tatus of surviving patients was assessed between May
nd August 2006. Event times were censored at the
tudy close-out date (May 15, 2006) for patients who
ere still being followed up without having experi-
nced the relevant events by the close-out date. Sta-
istical analyses were carried out using SAS, S-Plus,
nd StatXact statistical software. Transplant toxici-
ies were accessed using the Bearman criteria [10].
ESULTS
Thirty-eight patients were enrolled in the study.
he protocol speciﬁed that the primary group of
atients were those eligible patients who underwent a
ransplant. Three patients relapsed soon after regis-
ration and did not proceed to transplant; a fourth was
ubsequently rediagnosed as acute lymphoblastic leu-
emia (ALL) and removed from the study. The basic
emographic details of the 34 evaluable patients who
roceeded to transplant are summarized in Table 1.
Eighteen donors (53%) underwent 1 leukapheresis
nd 16 donors (47%) underwent a second. The me-
ian number of CD34 cells (1) collected per apheresis
as 3.8  106/kg recipient body weight (range 1.2-
4.6), and (2) infused was 5.3  106/kg (range 2.4-
4.6).
ransplant Toxicity
Transplants were extremely well tolerated. The
edian times to neutrophil and platelet recovery
0.5 and 20  109/L, respectively) posttransplant
ere 17 and 8.5 days, respectively. The platelet nadir
as 20  109/L in 6 of the 34 study patients (18%;
5% conﬁdence interval [CI] 7-33%) and 12 patients
35%; 95% CI 20-54%) did not require a platelet
ransfusion. Only 1 patient required parenteral nar-
otic analgesia for mucositis. Four patients required
able 1. Demographic Details of the 34 Study Patients
ale:female 23:11
edian age in years (range) 45 (19-60)
AB group
M1-2 20 (59%)
M4 7 (21%)
Other 7 (21%)
ytogenetics
Intermediate risk 29 (85%)
Adverse risk 5 (15%)
R after
First induction 29 (85%)
Second induction 5 (15%)
o. of consolidation cycles
One 11 (32%)
Two 23 (68%)
edian time (days) from start of induction
to transplant (range) 164 (77-497)R indicates complete remission.
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Peripheral Blood Stem Cell Sibling Allografts 563arenteral nutrition (1 for 3 days only and 3, in the
ontext of acute gastrointestinal GVHD, for 13 to 16
ays). In the ﬁrst 4 weeks grade II renal toxicity
ccurred in 3 patients, grade II stomatitis in 2 patients,
nd grade II and III hepatotoxicity in 2 patients.
here was no cardiac, bladder, pulmonary, neuro-
ogic or gastrointestinal toxicity in 97% of the study
atients.
VHD
Acute GVHD occurred as follows: grade 0: 24
atients (71%), grade I: 3 patients (9%); grade II: 4
atients (12%); grade III: 0 patients; and grade IV:
patients (9%). GVHD was fatal in all 3 patients with
rade IV disease. The incidence of cGVHD was as-
essed at 12 months posttransplant in 21 patients; 9
ere not evaluable because of death, 3 had early re-
apses (2 of whom underwent a second allograft), and
was nonassessable (failed to attend appointments).
even patients (33%) experienced no cGVHD; 9 (43%)
ad limited and 5 (24%) had extensive cGVHD. No
atient in ongoing remission has subsequently devel-
ped extensive cGVHD.
himerism
Data on the percentage of donor chimerism (my-
loid and T cell) were available at some stage for 28 of
he 34 study patients and were predominantly based
n peripheral blood samples. The median donor T
ell chimerism in the 24 patients in remission evalu-
ted in the vicinity of day 30 (days 20-35 inclusive) was
90%. These levels were subsequently sustained in
he absence of relapse: median (range) values in the
icinity of day 90 (days 60-120 inclusive, n  21) were
4 (36%-90)% and in the vicinity of day 180 (days
50-220, n  13) were 100 (67%-100)%. No patient
equired an early cyclosporine taper on the basis of
ow levels of donor T cell chimerism.
Myeloid engraftment was generally less rapid with
edian (range) values in the vicinity of day 30 (n 24)
f 81 (10-100)%, in the vicinity of day 90 (n  21) of
0 (90-100)%, and in the vicinity of day 180 (n  12)
f 100 (13-100)%. Patients relapsing prior to these
ime points were not included in this analysis.
Correlation coefﬁcients indicated no close asso-
iation between CD34 levels transfused and the
chieved maximum percentage donor T cell (r 
.33) or myeloid (r  0.31) chimerism at day 100.
here was no statistically signiﬁcant relationship be-
ween the severity of aGVHD and maximal levels of
onor chimerism in the ﬁrst 100 days following trans-
lant.
elapse, Outcome, and Survival
At the study close-out date, 18 patients were alive
n ongoing CR from the time of transplant. The cedian follow-up by the reverse Kaplan-Meier
ethod was 2.9 years (observed range, 1.6-5.3 years).
hirteen patients had relapsed, 6 before 4 months, 6
etween 4 and 12 months, and 1 at 46 months. The
elapse rates at 6 months, 1, and 2 years following
ransplant (with death without relapse regarded as
ensoring) were 21% (95% CI 10%-38%), 34% (95%
I 20%-52%), and 37% (95% CI 25%-55%), respec-
ively. In exploratory analyses, no signiﬁcant differ-
nces in the 1-year relapse-free rates were observed
ccording to (1) the number of induction cycles re-
uired to achieve CR (1: 71%, n  29 versus 2: 40%,
 5; P  .19); (2) cytogenetic risk group (adverse
3%, n  5 versus intermediate 68%, n  24; P 
32); and (3) the number of cycles of consolidation
1: 73%, n  11 versus 2: 63%, n  23; P  .31).
Three of the 13 patients who relapsed remain alive
n second CR. Seven patients were treated with fur-
her chemotherapy (myeloablative [n  3] or nonmy-
loablative [n  4]) and stem cell infusion, 2 of whom
emain alive in CR2 (8 and 11 months after relapse)
nd 2 who died of GVHD in CR2. Another patient
emains alive in remission after 14 months of single-
gent dasatinib for Ph AML. Eight patients who
elapsed subsequently died of progressive leukemia.
Thirteen patients have died, 8 of relapse, and 5 of
VHD in CR1 (n  3) or in CR2 (n  2). The
stimated DFS rates at 1 and 2 years following trans-
lant were 59% (95% CI 41%-74%) and 56% (95%
I 39%-71%), respectively, as presented in Figure 1.
f the patients transplanted on study, an estimated
4% (95% CI 56%-86%) survived for 1 year follow-
ng transplant and 68% (95% CI 50%-81%) survived
years (Figure 2).
ertility
Posttransplant semen analysis was performed in 4
onvasectomized males aged 19-51 years at trans-
lant. Sperm counts were 9 and 27  106/mL at 24
nd 39 months, 6.4  106/mL at 19 months, 28.6 
06/mL at 36 months, and 36 106/mL at 24 months,
espectively (normal count 20  106/mL).
Serial posttransplant hormonal measurements
ere available for 2 premenopausal females. In 1 pa-
ient, aged 40 years at transplant, spontaneous men-
truation occurred at 13 months posttransplant,
month after ceasing the oral contraceptive pill
OCP), with a hormonal proﬁle consistent with a
remenopausal state. Estradiol levels were 445, 1378,
nd 275 pmol/L at 24, 38, and 50 months. Her periods
ecame irregular after 4 years, and stopped completely
n the ﬁfth year (age 45) with a postmenopausal hor-
onal proﬁle. The second patient, aged 32 years at
ransplant, ceased the OCP at 8 months posttrans-
lant, with a return of menses within a month. Testing
onﬁrmed a premenopausal hormonal proﬁle and
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A. P. Grigg et al.564enses have been maintained for 3 years posttrans-
lant.
erformance Status
The Karnofksy score was 100% in 16 of the 18
urviving patients who never relapsed and 80% and
0% in the remaining 2 patients.
ISCUSSION
This prospective, multicenter study using a uni-
orm RIC protocol demonstrated that RIC was well
olerated, with minimal early morbidity, a low inci-
ence of severe aGVHD, and extensive cGVHD and
xcellent performance status in the relapse-free survi-
Figure 1. DFS, with 95% CI, forFigure 2. OS, with 95% CI, for all patieors. The OS and DFS rates are comparable with
hose reported with myeloablative conditioning [11]
nd broadly consistent with the published literature of
IC allografts for AML-CR1, reviewed by Lazarus
nd Rowe [12], together with a number of recent
ublications [13,14], in which in general the 2-3 year
FS was 50%.
A key issue in this ﬁeld is whether the intensity of
he conditioning preallograft has a substantial impact
n the relapse rate of AML in remission and OS.
etrospective studies comparing levels of condition-
ng intensity, although difﬁcult to interpret because of
mall numbers and imbalances in prognostic factors,
ave not demonstrated a consistent survival advantage
ith more intensive conditioning [12,15,16]. A difﬁ-
ents who underwent a transplant.nts who underwent a transplant.
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Peripheral Blood Stem Cell Sibling Allografts 565ulty is that the contribution of the low intensity of
he preparative regimen to relapse cannot be deﬁni-
ively assessed because of the confounding effect of
VHD-GVL interactions. In comparison with my-
loablative conditioning, RIC is generally associated
ith a lower incidence of both aGVHD and extensive
GVHD [17]. This is relevant as a recent report high-
ighted the importance of GVHD in reducing relapse
fter RIC for AML and myelodysplasia [18]. A Euro-
ean Group for Blood and Marrow Transplantation
tudy comparing RIC (n  315) with myeloablative
llografts (n  407) in AML patients over 50 years
emonstrated a statistically signiﬁcant, higher relapse
ate in the RIC group, perhaps related in part to a
ower incidence of grade II-IV aGVHD [19]. This
VHD-GVL interaction makes the intrinsic antileu-
emic potency of the conditioning regimen poten-
ially difﬁcult to delineate; it could be argued that the
ower relapse rates after “more intensive” RIC regi-
ens such as ﬂu-mel or ﬂu-busulfan, which generally
esult in early full donor T cell and myeloid chimer-
sm and a substantial rate of aGVHD [9,20], predom-
nantly relate to an early GVL effect rather than cy-
oreduction of residual leukemia by the conditioning
rotocol.
The ﬂu high-dose cyclophosphamide regimen
sed in this study is more lymphoablative than my-
loablative, and robust early donor T cell engraftment
as observed in the majority of patients, with myeloid
ngraftment being slower and more gradual. There
as no relationship between the risk of aGVHD and
aximum levels of donor lymphoid chimerism, with a
ow overall incidence of moderate to severe aGVHD
erhaps from minimal tissue damage and cytokine
elease [21]. Accordingly, it is difﬁcult to clearly
ttribute the relatively high early relapse rate to sub-
ptimal chemotherapy intensity or to inadequate
VL-GVHD effects. Inadequate induction and con-
olidation chemotherapy is unlikely to be relevant, as
ost study patients had received at least 1 course of
igh-dose cytarabine and idarubicin in induction or
onsolidation, and the relapse rate was not obviously
igher in the 3rd of patients who received only 1 course
f consolidation therapy.
The incidence of grade III-IV aGVHD in the
tudy was low (9%), but fatal in the 3 affected patients.
his suggests that although a nonmucositic regimen
ay have an impact on the overall incidence of mod-
rate to severe GVHD [18], some recipients are still
estined to develop refractory GVHD. T cell deple-
ion has permitted the safe application of the more
ggressive RIC allografts to older AML patients with
nrelated donors [22,23]. Whether the relapse rate
fter T cell depletion in this context is increased to the
xtent that it offsets any beneﬁt from a reduction in
VHD-related mortality is still open to question. tThe “time-lag” bias in which patients have to
urvive long enough in remission to reach transplant,
nd hence are a selected group, is well recognized as a
roblem in nonrandomized transplant studies [2].
here was a degree of selection in our study as the
edian time from the start of induction therapy to
ransplant was reasonably long at 5.5 months. Of note,
patients initially registered for the trial relapsed
rior to the anticipated time of transplant; their inclu-
ion in an intention-to-treat analysis would have in-
reased the estimated relapse rate at 1 year from 34%
o 39%.
Options for relapse after an RIC allograft include
or a combination of: withdrawal of immunosuppres-
ion, infusions of donor leukocytes or PBSC, conven-
ional dose chemotherapy, or a myeloablative allo-
raft. One theoretical attraction of an RIC allograft is
hat the modest organ toxicity may allow for a my-
loablative regimen to be used for subsequent relapse.
his approach was infrequently used in our study, as
nly 3 of 13 patients who relapsed subsequently had a
yeloablative allograft, 1 of whom is alive in CR2.
he available literature thus far suggests that pro-
onged DFS after therapy for relapse in this context is
nusual [24]. DLI alone does not seem effective [22],
ut late relapses may occasionally be effectively
reated with nonmyeloablative cytoreductive therapy
nd further PBSC infusions [25]. CR2 was achieved in
ll 4 study patients treated in this way with a durable
emission in 1 and death from GVHD in 2 patients.
The ﬂu-cyclo conditioning regimen was extremely
ell tolerated. Mucositis and other signiﬁcant nonhe-
atologic toxicities were rare and transfusion require-
ents were minimal. Delayed-onset aGVHD re-
orted to occur with other RIC regimens [26] was not
bserved, perhaps because of the continuation of cy-
losporine to 6 months after transplant in most pa-
ients. The incidence of extensive cGVHD in evalu-
ble patients in the ﬁrst year was low and the majority
f survivors who maintained remission have a normal
erformance status and excellent quality of life. The
imited data we collected on posttransplant fertility
uggest that spermatogenesis is not abolished, with
ormal sperm counts in all 3 men tested beyond 2
ears. Estradiol levels were within the premenopausal
ange in the 2 eligible women tested posttransplant
ith restoration of menses, although in 1 of these
enopause occurred at a relatively young age.
The results of our study are encouraging, but only
modest number of patients were enrolled. Moreover,
s the median age was somewhat lower than most RIC
tudies in this context, only sibling donors were used,
ew patients had adverse cytogenetics, and there was a
ubstantial time from induction therapy to transplant.
rguably, this represented a better risk group than
hose reported in other studies in this context.
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A. P. Grigg et al.566Ultimately the beneﬁts or otherwise of RIC versus
yeloablative conditioning for AML in remission will
nly be proved in prospective randomized trials in
hich the comparison groups are balanced for rele-
ant prognostic factors, including cytogenetic risk
roups, mutations within and overexpression of vari-
us genes [27], and duration of CR1. The results of
he current Cooperative German Transplant Study
roup trial in this context comparing ﬂu-TBI 8Gy
ith conventional cyclophosphamide-TBI 12Gy will
e of great interest.
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